Press Releases Nuevolution AB (publ)

Equities

NUE

SE0007730650

Delayed Nasdaq Stockholm Other stock markets			5-day change	1st Jan Change
- ^SEK	-.--%		-0.31%	+90.59%

2019	Amgen Inc. completed the acquisition of Nuevolution AB (OM:NUE) from Industrifonden, Skandinaviska Enskilda Banken AB (publ.) (OM:SEB A), Sunstone LSV Fund I K/S, SEB-Stiftelsen, Skandinaviska Enskilda Bankens Pensionsstiftelse, S-E-Bankens Utvecklingsstiftelse and others.	CI
2019	Nuevolution AB Reports Earnings Results for the First Quarter Ended of March 2019	CI

Press Releases

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Nuevolution publ : Svenska & English	19-04-17	PU
Nuevolution publ : Svenska & Engslish	19-04-17	PU
Nuevolution publ : AGM Proxy form UK	19-04-17	PU
Nuevolution publ : Corporate Governance Report 2018	19-04-08	PU
Nuevolution publ : EDISON MARCH 2019	19-03-19	PU
Nuevolution publ : EDISON SEPTEMBER 2018	18-09-25	PU
Nuevolution publ : REDEYE SEPTEMBER 2018	18-09-05	PU
Nuevolution publ : INTERIM REPORT Q2 2018	18-08-22	PU
Nuevolution publ : OFFENTLIGGÖR ATT IDENTITETEN FÖR SITT “CYTOKIN X”-PROGRAM ÄR INTERLEUKIN IL-17A OCH INLEDER ARBETET ATT SÖKA PARTNERSKAP FÖR SITT PROGRAM FÖR SMÅMOLEKYL IL-17A-IHÄMMARE RIKTAT MOT INFLAMMATORISKA SJUKDOMAR OFFENTLIGGÖR ATT IDENTITETEN FÖR SITT “CYTOKIN X”-PROGRAM ÄR INTERLEUKIN IL-17A OCH INLEDER ARBETET ATT SÖKA PARTNERSKAP FÖR SITT PROGRAM FÖR SMÅMOLEKYL IL-17A-IHÄMMARE RIKTAT MOT I	18-08-22	PU
Nuevolution publ : DISCLOSES THE IDENTITY OF ITS “CYTOKINE X” PROGRAM BEING INTERLEUKIN IL-17A, AND INITIATES PROMOTION OF ITS SMALL MOLECULE IL-17A INHIBITOR PROGRAM TARGETING INFLAMMATORY DISEASES DISCLOSES THE IDENTITY OF ITS “CYTOKINE X” PROGRAM BEING INTERLEUKIN IL-17A, AND INITIATES PROMOTION OF ITS SMALL MOLECULE IL-17A INHIBITOR PROGRAM TARGETING INFLAMMATORY DISEASES	18-08-22	PU
Nuevolution publ : AMGEN UTNYTTJAR SINA OPTIONSRÄTTIGHETER I FÖRSTA PROGRAMMET INOM FORSKNINGSSAMARBETET TILLSAMMANS MED NUEVOLUTION KRING MULTIPLA MÅL	18-07-18	PU
Nuevolution publ : OFFENTLIGGÖR PROSPEKT I SAMBAND MED LISTBYTET TILL NASDAQ STOCKHOLM	18-06-20	PU
Nuevolution publ : BESLUT VID ÅRSSTÄMMA I NUEVOLUTION AB (PUBL)	18-05-28	PU
Nuevolution publ : HAR SLUTFÖRT EN RIKTAD EMISSION SOM TILLFÖR BOLAGET 110 MSEK FÖRE TRANSAKTIONSKOSTNADER	18-05-25	PU
NUEVOLUTION (PUBL) : ANNOUNCES TIMING FOR THE RELEASE AND WEBCAST OF THE FIRST QUARTER 2018 INTERIM RESULTS FROM JANUARY – MARCH 2018	18-04-30	PU
Nuevolution publ : BOARD OF DIRECTORS TO BE REDUCED FROM SIX TO FIVE MEMBERS. FREDRIK ARP NOT TO SEEK RE-ELECTION	18-04-24	PU
Nuevolution publ : THE DANISH EASTERN HIGH COURT REVOKES THE MARITIME AND COMMERCIAL HIGH COURT’S DECISION OF 22 FEBRUARY 2016 IN FAVOUR OF NUEVOLUTION’S REQUEST	17-12-08	PU
Nuevolution : to Present New Data on its BET BD1 Program Supporting Effect in Psoriasis/Atopic Dermatitis	17-11-27	PR
Nuevolution publ : PRESENTATION FOR NUEVOLUTION’S ANNUAL GENERAL MEETING AND VIDEO MATERIAL BASED ON THE ANNUAL REPORT 2016/17 NOW AVAILABLE	17-10-12	PU
NUEVOLUTION (PUBL) : INTENDS TO MOVE THE LISTING OF ITS SHARES TO NASDAQ STOCKHOLM’S MAIN MARKET DURING THE FISCAL YEAR 2017/18	17-09-18	PU

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Press Releases Nuevolution AB (publ)

Equities

NUE

SE0007730650

Press Releases

Filters